Human IL-29 ELISA kit
Product Specifications
- Catalogue N°
- 873.050.048 - 1 x 48 Discovery (pre-coated)
873.050.096 - 1 x 96 (pre-coated)
873.050.192 - 2 x 96 (pre-coated) - Assay Range
- 250 pg/ml - 7.8 pg/ml
- Sensitivity
- 5.9 pg/ml
- Target species
- Human
- Specificity
- Recognizes both natural and recombinant human IL-29
- Incubation
- 2h45
- Sample Type
- Cell culture supernatant, serum or plasma tested, other body fluids suitable
- Sample Size
- 50 µl
- Cross Reaction
- No cross reactivity observed with IFNa2, IL-28A, IL-28B, IFNg, IL-10, IL-24, IP-10, IL-31, IL-34 and GM-CSF
- Kit Content
- Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
- Synonym
- Interferon lambda 1
- ZCYTO21
BACKGROUND
IL-29 was discovered in 2003. Also termed IFNl1, IL-29 belongs to the type III subset of IFN family with IL-28A and IL-28B, respectively IFNl2 and IFNl3. The IFNl genes are clustered together on human chromosome 19 and are composed of multiple exons, resembling the structural organization of genes encoding IL-10-related cytokines. The IL-29 gene encodes 20 kDa secreted monomeric protein.
The IFNl proteins bind and signal through a heterodimeric receptor composed of the unique IFNlR1 chain (also known as IL-28RA) and the shared IL-10Rb chain which is also a part of the receptor for IL-10, IL-22. IFN type I receptors are largely restricted to cells of epithelial origin. They activate the same intracellular signaling pathway and trigger many of the same biological activities, including antiviral and antitumor activity, in a wide variety of target cells.
IL-29 plays a role in the antiviral defence, predominantly in the epithelial tissues. It has been described as a therapeutic agent to treat patients with chronic hepatitis C virus by inhibiting B and C hepatitis virus replication.
It could be the main inhibitor to innate immunity and has demonstrated activity at the interface between innate and adaptive immunity. IFNl inhibits also the Th2 response and acts directly on CD4+ T-Cells and dendritic cells, effects are not accompanied by a complementary elevation of Th1.
Its use as a potential therapeutic agent for allergic asthma is under study and its anti-proliferative and anti-tumor activities make it a novel target for the treatment and control of some cancer.
Version 5 - 11.21
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.